Evercore ISI Positive on Insmed (INSM) into FDA Ad Comm

July 31, 2018 3:58 PM EDT
Get Alerts INSM Hot Sheet
Price: $23.15 +4.47%

Rating Summary:
    17 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 24
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Evercore ISI analsyt Josh Schimmer is positive on Insmed (NASDAQ: INSM) into the August 7th Ad Comm with briefing documents expected August 3rd.

Schimmer notes the Antimicrobial Drugs Advisory Committee panel appears to be generally constructive over the past couple of years, but are sticklers if they feel that a trial wasn’t conducted properly or if there are inconsistent result.

The analyst said given the size and conduct of the CONVERT study for ALIS and supporting P2 data, they think this bodes very well for a positive review

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot Comments, Trader Talk

Related Entities

AdCom, FDA